The LDN 2021 Conference Recordings Now Available with up to 29 CME Credits [More Details]
Low-dose Naltrexone: An Alternative Treatment for Erythrodermic Psoriasis (Abstract)
Low-dose Naltrexone: An Alternative Treatment for Erythrodermic Psoriasis
This clinical case demonstrates the benefits of patient treatment with low-dose naltrexone (LDN) used in erythrodermic psoriasis. A patient with a confirmed history of psoriasis by histopathology was treated with 4.5 mg of LDN during six months follow-up after an erythrodermic psoriasis flare-up. The patient showed significant improvement in her flare-up and psoriasis remission after only three months of 4.5 mg of LDN on a daily basis. Low-dose naltrexone (LDN) has proven to be a great ally in treating erythrodermic psoriasis flare-ups as an alternative treatment with less collateral side effects.